Supporting his view, JPMorgan analyst Samik Chatterjee, on Dec. 16, upgraded Keysight from Neutral to Overweight and announced a $200 price target.
Shares Views On These Health Care Names
Cramer recommended to wait for ADMA Biologics, Inc. (NASDAQ:ADMA) to come down before pulling the trigger. “I don't have a catalyst,” he noted.
The company's stock has jumped more than 206% over the past year.
“I just think that they should be making money,” Cramer said when asked about NovoCure Limited (NASDAQ:NVCR). “Let's see some money made by Novocure and then we can get behind it.”
Novocure, meanwhile, on Jan. 13, reported preliminary net revenues for FY2024 of $605.2 million and preliminary net revenues of $161.3 million for the fourth quarter.
Other Stocks In Focus
When asked about Lockheed Martin Corporation (NYSE:LMT), he said, “I do not want to get in the way of the Palantir buzz saw because that's very close to Elon Musk.”
Lockheed Martin, meanwhile, on Jan. 28, reported mixed fourth-quarter 2024 results. The company reported a net sales decline of 1.3% year-over-year to $18.622 billion, missing the consensus of $18.91 billion. LMT reported Adjusted EPS of $7.67, beating the consensus of $6.64.
Price Action:
- Lockheed Martin shares fell 0.7% to settle at $454.36 on Wednesday.
- ADMA Biologics shares gained 1.3% to close at $16.38 during the session.
- Novocure shares fell 0.2% to settle at $25.52 on Wednesday.
- Keysight shares rose 0.2% to settle at $168.33 on Wednesday.
Read Next:
Image: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
